INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILDGlobeNewsWire • 07/06/25
Why This Looming Supreme Court Decision Could Rattle Gilead SciencesInvestors Business Daily • 06/27/25
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 DegradersBusiness Wire • 06/25/25
Gilead's twice-yearly PrEP injection wins FDA approval, analysts see solid launch aheadProactive Investors • 06/18/25
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?Investors Business Daily • 06/18/25
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of ProtectionBusiness Wire • 06/18/25
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new optionCNBC • 06/18/25
GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & KorsinskyAccesswire • 06/17/25
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationAccesswire • 06/17/25
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities FraudAccesswire • 06/16/25
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost MoneyAccesswire • 06/16/25
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the InvestigationAccesswire • 06/16/25
Investigation Alert: Gilead Sciences, Inc. (GILD) Under Scrutiny - Contact Levi & Korsinsky for DetailsAccesswire • 06/15/25
Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities InvestigationAccesswire • 06/15/25